Development and validation of a nomogram for risk prediction of nephrolithiasis recurrence in patients with primary hyperparathyroidism

Yihong Zhou1,2, Xi Chu1,2, Dong Jiang1,2, Xiang Wu1,2, Jiarong Xu1,2, Hao Qi1,2, Yuxin Tang1,2* and Yingbo Dai1,2*

1Department of Urology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China, 2Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China

Background: Nephrolithiasis is a common complication of primary hyperparathyroidism (PHPT), and the recurrence of nephrolithiasis in patients with PHPT is also an urgent concern. What is worse, there is a scarcity of recommended evaluation to predict the risk of nephrolithiasis recurrence in patients with PHPT. This study was aimed to develop and validate a nomogram to facilitate risk assessment in patients with PHPT.

Methods: A total of 197 patients with PHPT were retrospectively included in this study from September 2016 to August 2021. Patients’ demographic data, blood test parameters, urinalysis, stone parameters, and surgical intervention were collected. Extracted variables were submitted to a least absolute shrinkage and selection operator (LASSO) regression model. A nomogram was built and validated according to the area under the curve (AUC) value, calibration curve, and decision curve analysis.

Results: According to the LASSO regression and logistic regression analyses, five predictors were derived from 22 variables: creatinine, uric acid, bilateral stone, multiplicity, and surgery. The AUC and concordance index of the training cohort and validation cohort were 0.829 and 0.856, and 0.827 and 0.877, respectively. The calibration curve analysis and the decision curve analysis showed that the nomogram had an adequate prediction accuracy.

Conclusion: We built a useful nomogram model to predict the risk of nephrolithiasis recurrence in patients with PHPT. This would assist clinicians to provide appropriate advices and managements for these patients.

KEYWORDS
primary hyperparathyroidism, nephrolithiasis, recurrence, nomogram, risk prediction
Introduction

Primary hyperparathyroidism (PHPT) is the third most common endocrine disease after diabetes mellitus and thyroid disorders, with an incidence of approximately 65.5 and 24.7 individuals per 100,000 in women and men, respectively (1, 2). Generally, PHPT occurs in post-menopause women. However, no significant difference exists in the population under the age of 45 years (3). Parathyroid dysfunction is the main cause of PHPT, with excessive release of parathyroid hormone (PTH) and disorder of normal regulation. As a result of increased level of PTH, the homeostasis of calcium and phosphate is disrupted, which leads to hypercalcemia through increased renal tubular calcium reabsorption (4). While hypercalcemia is a contributing factor in stone formation, the kidney is a principal target of PHPT, resulting in nephrolithiasis.

It has been reported that about 10% of the patients had pre-existing nephrolithiasis at the time of diagnosis of PHPT (5). Moreover, the incidence of nephrolithiasis in patients with PHPT is four times that of the general population (6). In addition to the high incidence, the nephrolithiasis recurrence in patients with PHPT is also an urgent concern. Huang et al. followed a cohort of 1,252 patients with PHPT and found an overall nephrolithiasis recurrence rate of 31.3%. For patients under observation treatment, the nephrolithiasis recurrence rate was 13.7%, 22.3%, and 29.4% in the 5-, 10-, and 15-year follow-up, respectively (7). Some studies have suggested several factors for kidney stone recurrence, such as age, body mass index (BMI), and 24-h urine parameters (8–10). However, to our knowledge, there is a lack of recommended evaluation to predict the risk of nephrolithiasis recurrence in patients with PHPT.

The main objective of this study was therefore to identify the significant predictive factors for nephrolithiasis recurrence in patients with PHPT and to develop and validate a nomogram to facilitate risk assessment. This would assist clinicians to provide appropriate advices and managements for these patients.

Methods

Data sources and study subjects

This study was approved by the Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-sen University (No. K73-1). Data were retrospectively obtained from the medical records between September 2016 and August 2021 at the Fifth Affiliated Hospital of Sun Yat-sen University. All patients were diagnosed as nephrolithiasis with PTHH. PTHH was defined as PTH level > 69 pg/ml with a normal or elevated albumin-adjusted calcium (11, 12). The exclusion criteria were as follows: (1) secondary hyperparathyroidism, such as chronic kidney disease, vitamin D deficiency, and gastrointestinal malabsorption; and (2) intake of medications such as diuretics, hydrochlorothiazide, and lithium.

Variables collected and outcomes

Data on the following parameters were collected: sex, age, BMI, medical history (hypertension and diabetes mellitus), blood test parameters (corrected calcium, PTH, phosphorus, chloride, potassium, triglycerides, high-density lipoprotein, low-density lipoprotein, alkaline phosphatase, creatinine, and uric acid), urinalysis (pH and crystal), stone parameters (bilateral stone, multiplicity, and stone composition), and intervention (ESWL, PCNL, and RIRS). Albumin-adjusted calcium level was calculated as follows: corrected calcium (mmol/L) = measured calcium (mmol/L) + (40 – serum albumin concentration (g/L) × 0.02).

Patients were followed up every 3–6 months, with a range of 3–64 months and a mean follow-up of 25 months. Recurrence of nephrolithiasis was the primary endpoint, which was defined as a new kidney stone on ultrasound and/or CT scan occurring more than 30 days after intervention.

Statistical analysis

SPSS 19.0 (IBM SPSS, Inc., Chicago, IL, USA) and R software (R version 4.1.1, R Project, www.r-project.org) were used for data analysis. Parameters were described as mean ± SD. When comparing the baseline characteristics, chi-square test or Fisher’s exact test was performed for categorical variables and Wilcoxon signed-rank test for quantitative variables. Modeling time to recurrence of nephrolithiasis was performed using Kaplan–Meier survival analysis. A p-value < 0.05 was considered to be statistically significant.

The overall cohort was randomly assigned 70% of the patients to the training cohort and 30% to the validation cohort. Extracted variables were submitted to a least absolute shrinkage and selection operator (LASSO) regression model for data dimensionality reduction and feature selection. Then, independent risk factors associated with recurrence of nephrolithiasis were selected using the logistic regression analysis, and a nomogram was built in the training cohort. A receiver operating characteristic (ROC) curve was subsequently drawn on the basis of predictive factors, and the sensitivity and the specificity were evaluated using the area under the curve (AUC) value. The concordance index (C-index) was used to evaluate the discrimination ability of the nomogram. Calibration curve and decision curve analysis were performed to examine the performance characteristics and assess the clinical benefits. Finally, the validation cohort was used to validate the nomogram constructed in the training cohort.
Results

Patient characteristics

A total of 197 patients were included in the current study, with 105 men and 92 women. According to the ratio of 7:3, 140 patients were randomly assigned into the training cohort and 57 patients in the validation cohort. The clinical characteristics of patients in the training cohort and the validation cohort are summarized in Table 1. There was no difference in distribution of all characteristics between the training cohort and the validation cohort.

Recurrence of nephrolithiasis

After surgical intervention, 59 patients had at least one recurrent episode of nephrolithiasis. Overall recurrence rate of nephrolithiasis was 29.9%. Figure 1 shows the cumulative recurrence rate of the entire cohort. Detailed characteristics of patients with or without nephrolithiasis recurrence are summarized in Supplementary Table 1.

Independent predictors for nephrolithiasis recurrence

To screen out the independent predictors, all variables were preliminarily analyzed using LASSO analysis in the training cohort. Five potential predictors were derived from 22 variables (Figure 2). Finally, creatinine, uric acid, bilateral stone, multiplicity, and surgery were identified. Table 2 shows the Odds ratio (OR) and 95% CI values of these predictors using the logistic regression analysis.

Development and validation of the nomogram

A nomogram was then constructed on the basis of the abovementioned five predictive factors for nephrolithiasis recurrence in the training cohort (Figure 3). The nomogram indicated that multiplicity has the greatest influence on the nephrolithiasis recurrence of patients with PHPT, followed by surgery, bilateral stone, creatinine, and uric acid. The AUCs of the training cohort and validation cohort were 0.829 and 0.856, respectively (Figure 4). In addition, the C-index values of the training cohort and validation cohort were 0.827 and 0.877, respectively. Both the AUC and C-index value indicated that this nomogram had medium prediction accuracy. Moreover, this nomogram also showed adequate prediction accuracy on the basis of the calibration curve analysis (Supplementary Figure 1).

Furthermore, the net benefit was comparable with several overlaps on the basis of the nephrolithiasis recurrence risk nomogram according to the decision curve analysis (Supplementary Figure 2).

Discussion

Nephrolithiasis is a common disease in the general population, with an estimated prevalence of 10%–15% (13, 14). This condition is a considerable economic burden, costing the healthcare system more than $10 billion per year (15). In addition, a 50% risk of nephrolithiasis recurrence is observed at 7–10 years in the absence of specific treatment (10, 16). Whereas for patients after surgical treatment, 17%–21% had recurrent nephrolithiasis requiring a repeat surgery (17, 18). For patients treated with percutaneous nephrolithotomy (PCNL), the recurrence rate can be as high as 40% (19). In addition, when with certain comorbidities, the risk of nephrolithiasis recurrence will increase. For example, 23% patients with type 2 diabetes will have a stone recurrence, and the recurrence rate in patients with metabolic syndrome is 3.2-fold higher compared with those in the control group (19, 20).

PHPT is a common endocrine disease characterized by hypercalcemia, which leads to a high incidence and recurrence rate of nephrolithiasis. Mollerup and Lindewald found that the recurrence rate of nephrolithiasis within 5 years was 30% in patients with PHPT (21). Similarly, in a cohort of 1,252 patients with PHPT, the overall recurrence rate of nephrolithiasis was 31.3% during an average follow-up of 8 years (7). In the current study, the overall recurrence rate of nephrolithiasis was 29.9%, which was consistent with the above studies.

Although with high recurrence rate of nephrolithiasis in patients with PHPT, no prediction model for nephrolithiasis recurrence in patients with PHPT has been reported to date. In the present study, a nomogram for risk prediction of nephrolithiasis recurrence in patients with PHPT was developed and validated. The final model was based on five predictors: creatinine, uric acid, bilateral stone, multiplicity, and surgery. The AUC and C-index of the training cohort and validation cohort were 0.829 and 0.856, and 0.827 and 0.877, respectively. Both the AUC and C-index value suggested that the nomogram could provide good prediction. This model would be helpful to provide appropriate advices and managements for patients with PHPT.

Stone burden is widely used for determining the management of urolithiasis. For kidney stones, evaluation of stone burden has shown to be a predictor of the clinical outcome of different surgical treatments, including flexible ureteroscopy and PCNL (22, 23). Recently, stone burden has also been proved to be associated with the nephrolithiasis recurrence (24, 25). Stone multiplicity, stone size, total stone volume, and bilateral stones are used to quantify stone burden. Observational and
### TABLE 1  Comparison of characteristics between the training and validation cohort.

| Characteristic                        | All cases n = 197 | Training cohort n = 140 | Validation cohort n = 57 | p value |
|---------------------------------------|-------------------|-------------------------|--------------------------|---------|
| Sex                                   |                   |                         |                          | 0.845   |
| Male                                  | 105               | 74                      | 31                       |         |
| Female                                | 92                | 66                      | 26                       |         |
| Age (years)                           |                   |                         |                          | 0.109   |
| <45                                   | 60                | 39                      | 21                       |         |
| 45–65                                 | 109               | 84                      | 25                       |         |
| >65                                   | 28                | 17                      | 11                       |         |
| Hypertension                          |                   |                         |                          | 0.745   |
| Yes                                   | 48                | 35                      | 13                       |         |
| No                                    | 149               | 105                     | 44                       |         |
| Diabetes mellitus                     |                   |                         |                          | 0.711   |
| Yes                                   | 27                | 20                      | 7                        |         |
| No                                    | 170               | 120                     | 50                       |         |
| BMI (kg/m²)                           |                   |                         |                          | 0.360   |
| <25                                   | 118               | 87                      | 31                       |         |
| 25–30                                 | 60                | 42                      | 18                       |         |
| >30                                   | 19                | 11                      | 8                        |         |
| Corrected calcium (mmol/L)            |                   |                         |                          | 0.241   |
| ≤2.52                                 | 167               | 116                     | 51                       |         |
| >2.52                                 | 30                | 24                      | 6                        |         |
| PTH (pg/ml)                           |                   |                         |                          | 0.703   |
| ≤90                                   | 125               | 90                      | 35                       |         |
| >90                                   | 72                | 50                      | 22                       |         |
| Phosphorus (mmol/L)                   |                   |                         |                          | 0.627   |
| ≤0.85                                 | 46                | 34                      | 12                       |         |
| >0.85                                 | 151               | 106                     | 45                       |         |
| Chlorine (mmol/L)                     |                   |                         |                          | 0.908   |
| ≤105                                  | 151               | 107                     | 44                       |         |
| >105                                  | 46                | 33                      | 13                       |         |
| Potassium (mmol/L)                    |                   |                         |                          | 0.723   |
| ≤4.0                                  | 86                | 60                      | 26                       |         |
| >4.0                                  | 111               | 80                      | 31                       |         |
| Triglycerides (mmol/L)                |                   |                         |                          | 0.303   |
| ≤1.88                                 | 153               | 106                     | 47                       |         |
| >1.88                                 | 44                | 34                      | 10                       |         |
| HDL (mmol/L)                          |                   |                         |                          | 0.429   |
| ≤1.08                                 | 102               | 75                      | 27                       |         |
| >1.08                                 | 95                | 65                      | 30                       |         |
| LDL (mmol/L)                          |                   |                         |                          | 0.326   |
| ≤3.12                                 | 161               | 112                     | 49                       |         |
| >3.12                                 | 36                | 28                      | 8                        |         |
| ALP (U/L)                             |                   |                         |                          | 0.949   |
| ≤90                                   | 148               | 105                     | 43                       |         |
| >90                                   | 49                | 35                      | 14                       |         |
| Creatinine (mg/dl)                    |                   |                         |                          | 0.714   |
| ≤0.916                                | 79                | 55                      | 24                       |         |
| >0.916                                | 118               | 85                      | 33                       |         |
| Uric acid (μmol/L)                    |                   |                         |                          | 0.889   |

(Continued)
retrospective studies showed that the number of stones detected on imaging are associated with higher rates of recurrence (9, 26). Moreover, bilateral stones are also predictive of nephrolithiasis recurrence. Selby and colleagues found that patients with bilateral stones had a 1.8-fold increase in risk for encountering future symptomatic stone events (27). The current model indicated that stone multiplicity has the greatest influence on the nephrolithiasis recurrence of patients with PHPT (OR = 15.064, 95% CI: 3.669–92.151, \( p < 0.001 \)). In addition, bilateral stone was also one of the predictive factors (OR = 2.895, 95% CI: 1.160–7.523, \( p = 0.025 \)). These findings indicate that stone burden is a key predictor for nephrolithiasis recurrence of patients with PHPT.

Extracorporeal shock wave lithotripsy (ESWL), PCNL, and retrograde intrarenal surgery (RIRS) are the three major treatments for nephrolithiasis. With simple anesthesia requirement and being an outpatient surgery, ESWL is a choice with better patient acceptance. However, a lower stone free rates in patients after ESWL was identified when the effectivenes was investigated (28, 29). Several studies also compared the rate of stone recurrence between ESWL and PCNL, RIRS. During an average follow-up period of 19.2 years, Amy et al. found that ESWL had a higher stone recurrence than PCNL (53.3% vs. 36.8%, \( P = 0.033 \)) (30). Similarly, increased probability of stone recurrence after ESWL was found when compared with RIRS (35.4% vs. 17.2%, \( P = 0.009 \)) (31). In the current study, we found surgical intervention was a predictive factor for nephrolithiasis recurrence in patients with PHPT. Patients with ESWL would encounter a higher rate

![Figure 1: The cumulative recurrence rate of nephrolithiasis in patients with primary hyperparathyroidism.](image-url)
of stone recurrence compared with those treated with PCNL and RIRS.

Uric acid is the end product of purine metabolism, and high level of serum uric acid (SUA) is associated with several health disorders, including diabetes, cardiovascular diseases, metabolic syndrome, and cancer. A clear association has been identified between SUA and nephrolithiasis (32). PTH could decrease the secretion of uric acid in the renal tubular, leading to an increase of SUA. Recently, studies showed that patients with PHPT had a significantly higher level of SUA compared with those without PHPT (33). In this study, our results indicated that high level of SUA increased the rate of nephrolithiasis recurrence. Interestingly, outcomes of randomized controlled trials showed that SUA-lowering treatment decreased the risk of nephrolithiasis recurrence (34). Thus, controlling the level of SUA may be a potential measure to reduce stone recurrence in patients with PHPT.

There are certain limitations in the present study. First, although with a relatively good prediction accuracy, our study was retrospectively designed in a single center and lacked an

| Intercept and variable | $\beta$ | Odds ratio (95% CI) | $p$ value |
|------------------------|--------|---------------------|----------|
| Intercept              | $-2.955$ | $0.052 (0.009$-$0.218)$ | $<0.001$ |
| Creatinine             | $0.940$ | $2.560 (1.003$-$6.819)$ | $0.053$ |
| Uric acid              | $0.909$ | $2.483 (1.017$-$6.197)$ | $0.047$ |
| Bilateral stone        | $1.063$ | $2.895 (1.160$-$7.523)$ | $0.025$ |
| Multiplicity           | $2.712$ | $15.064 (3.669$-$92.151)$ | $<0.001$ |
| Surgery                | $-1.578$ | $0.206 (0.032$-$1.136)$ | $0.076$ |
| PCNL                   | $-1.735$ | $0.176 (0.029$-$0.936)$ | $0.046$ |

TABLE 2 Logistic regression analysis of independent risk factors associated with recurrence of nephrolithiasis in the training cohort.
external population to validate the predictive model. Second, studies have showed some potential variables that are related to nephrolithiasis recurrence, such as 24-h urine collection and parathyroidectomy. The results of existing research studies are contradictory (7, 35–37), and we tried to elucidate their roles in nephrolithiasis recurrence in patients with PHPT. However, these variables were not included due to the small number. To provide a more convinced result, a multi-center and large sample cohorts need be performed in the future.

**Conclusion**

In conclusion, we built a useful nomogram model to predict the risk of nephrolithiasis recurrence in patients with PHPT. This would assist clinicians to provide appropriate advices and managements for these patients.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**Ethics statement**

The studies involving human participants were reviewed and approved by the Ethics Committee of the fifth affiliated hospital of Sun Yat-sen University (No. K73-1). The patients/participants provided their written informed consent to participate in this study.

**Author contributions**

YZ, YT, and YD designed the concept of the study. YZ, XC, and DJ collected and analyzed the data. XW, JX, and HQ critically revised the analysis. YZ wrote the draft manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**Funding**

This study was supported by the Guangdong Medical Research Foundation (No. A2021358 to YZ) and the Natural Science Foundation of Guangdong Province (No. 2019A1515012116 to YD).
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.947497/full#supplementary-material

References

1. Sharma S, Rastogi A, Bhadada SK, Singh N, Varshney S, Behera A, et al. Prevalence and predictors of primary hyperparathyroidism among patients with urolithiasis. *Endocrinol Pract* (2017) 23(11):1341–5. doi: 10.4158/ep171759.Cr

2. Yeh MW, Itaue PH, Zhou HC, Nishimoto S, Liu IL, Harazi A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. *J Clin Endocrinol Metab* (2013) 98(5):1122–9. doi: 10.1210/jc.2012-4022

3. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1980–2001: An update on the changing epidemiology of the disease. *J Bone Miner Res* (2006) 21(1):171–7. doi: 10.1359/jbmr.050910

4. Dandurand K, Ali DS, Khan AA. Primary hyperparathyroidism: A narrative review of diagnosis and medical management. *J Clin Med* (2021) 10(8):1604. doi: 10.3390/jcm10081604

5. Assaadpour Y, Zhou H, Kuo EL, Haigh PL, Adams AL, Yeh MW. End-organ effects of primary hyperparathyroidism: A population-based study. *Surgery* (2019) 165(1):99–104. doi: 10.1016/j.surg.2018.04.088

6. Sub JM, Cronan JJ, Monchik JM. Primary hyperparathyroidism: Is there an increased prevalence of renal stone disease? *Am J Roentgenol* (2008) 191(3):908–11. doi: 10.2214/ajr.07.3160

7. Huang SY, Burchette R, Chung J, Haigh PL. Parathyroidectomy for nephrolithiasis in primary hyperparathyroidism: Beneficial but not a panacea. *Surgery* (2022) 171(2):29–34. doi: 10.1016/j.surg.2021.03.077

8. D’Costa MR, Haley WE, Mara KC, Enders PT, Vrtiska TJ, Pais VM, et al. Symptomatic and radiographic manifestations of kidney stone recurrence and their prediction by risk factors: A prospective cohort study. *J Am Soc Nephrol* (2019) 30(7):1251–60. doi: 10.1681/asn.2018121241

9. Vaughan LE, Enders FT, Lieske JC, Pais VM, Rivera ME, Mehta RA, et al. Incidence and prevalence of primary hyperparathyroidism among patients with urolithiasis. *Am J Kidney Dis* (2020) 52(9):1651–5. doi: 10.1016/s0272-6386(20)32476-0

10. Williams KW, Fairchild B, Brereton PJ, Hitchcock J. Screening for primary hyperparathyroidism in a tertiary stone clinic, a useful endeavor. *Int Urol Nephrol* (2020) 52(9):1651–5. doi: 10.1007/s11255-020-01247-0

11. Wu KCJ, Anpalahan M. Normocalcaemic primary hyperparathyroidism. Is nephrolithiasis more common than osteoporosis? *Intern Med J* (2021). doi: 10.1111/imi.15502

12. Rule AD, Lieske JC, Pais VM Jr. Management of kidney stones in 2020. *Jama* (2020) 323(19):1961–2. doi: 10.1001/jama.2020.0662

13. Finger M, Finger E, Bellucci A, Malieckal DA. Medical management for the prevention of kidney stones. *Postgrad Med J* (2021). doi: 10.1136/postgradmedj-2021-140970

14. Pearse MS, Calhoun EA, Curhan GC. Urolithic diseases in America project: Urolithiasis. *J Urol* (2005) 173(3):848–57. doi: 10.1016/j.juro.2004.04.009

15. Stierer R. Nutrition and kidney stone disease. *Nutrients* (2021) 13(9):1917. doi: 10.3390/nu13091917

16. Iremashvili V, Li S, Penniston KL, Best SL, Hedican SP, Nakada SY. External validation of the recurrence of kidney stone nomogram in a surgical cohort. *J Endourol* (2019) 33(6):475–9. doi: 10.1089/end.2018.0893

17. Iremashvili V, Li S, Dresner SL, Best SL, Hedican SP, Nakada SY. Gender-related differences in the risk factors for repeat stone surgery. *Urolithiasis* (2021) 49(5):471–6. doi: 10.1007/s00240-021-01255-5

18. Akinman T, Binhay M, Erbin A, Tepeler A, Sari E, Kucuktopcu O, et al. The impact of metabolic syndrome on long-term outcomes of percutaneous nephrolithotomy (Pcnl). *BJU Int* (2021) 110(11 Pt C):E709–83. doi: 10.1111/1445-410X.13158.x

19. Prasánchammitr P, Monga M. Predictive factors for kidney stone recurrence in type 2 diabetes mellitus. *Urology* (2021) 143:85–90. doi: 10.1016/j.urology.2020.04.067

20. Mollerup CL, Lindewald H. Renal stones and primary hyperparathyroidism: Natural history of renal stone disease after successful parathyroidectomy. *World J Surg* (1999) 23(2):173–5. doi: 10.1007/pk0013175

21. Ito H, Kawahara T, Terasa H, Ogawa T, Yao M, Kubota Y, et al. Utility and limitation of cumulative stone diameter in predicting urinary stone burden at flexible ureteroscopy with holmium laser lithotripsy: A single-center experience. *PloS One* (2013) 8(6):e65060. doi: 10.1371/journal.pone.0065060

22. Noureddin YA, Andonian S. Do percutaneous nephrolithotomy outcomes depend on the way stone burden is measured? *J Endourol* (2015) 29(9):975–7. doi: 10.1089/end.2015.29022.yun

23. Ito K, Takahashi T, Somiya S, Kanno T, Higashi Y, Yamada H. Predictors of repeat surgery and stone-related events after flexible ureteroscopy for renal stones. *Urology* (2021) 154:96–102. doi: 10.1016/j.urology.2021.02.025

24. Wang X, Zhang Y, Zhao F, Li J, Yuan Y. Symptomatic recurrence rate of upper urinary tract calculi in children after endourological procedures. *J Pediatr Urol* (2021) 17(2):141.e1–141.e7. doi: 10.1016/j.jpurol.2021.09.023

25. Kang HW, Lee SK, Kim WT, Kim YJ, Yun SJ, Lee SC, et al. Natural history of asymptomatic renal stones and prediction of stone related events. *J Urol* (2013) 189(5):1740–6. doi: 10.1016/j.juro.2012.11.113

26. Selby MG, Vrtiska TJ, Krambeck AE, McCollough CH, Eldherrine HY, Bergstralh EJ, et al. Quantification of asymptomatic kidney stone burden by computed tomography for predicting future symptomatic stone events. *Urology* (2015) 85(1):45–50. doi: 10.1016/j.urology.2014.08.031

27. Sener NC, Imamoglu MA, Bas O, Ozturk U, Goktug LN, Huygun C, et al. Prospective randomized trial comparing shock wave lithotripsy and flexible ureterorenoscopy for lower pole stones smaller than 1 Cm. *Urolithiasis* (2014) 42(2):127–31. doi: 10.1007/s00240-013-0618-x

28. Kalldonis P, Ntaisiotis P, Somani B, Adamou C, Emilianis E, Knoll T, et al. Systematic review and meta-analysis comparing percutaneous nephrolithotomy, retrograde intrarenal surgery and shock wave lithotripsy for lower pole renal stones less than 2 Cm in maximum diameter. *J Urol* (2020) 204(3):427–33. doi: 10.1097/aju.0000000000001013

29. Krambeck AE, LeRoy AJ, Patterson DE, Gettman MT. Long-term outcomes of percutaneous nephrolithotomy compared to shock wave lithotripsy and
conservative management. J Urol (2008) 179(6):2233–7. doi: 10.1016/j.juro.2008.01.115

31. Ozgor F, Sahin M, Yanaral F, Savun M, Sarilar O. Flexible ureterorenoscopy is associated with less stone recurrence rates over shockwave lithotripsy in the management of 10-20 millimeter lower pole renal stone: Medium follow-up results. Int Braz J Urol (2018) 44(2):314–22. doi: 10.1590/s1677-5538.ibju.2017.0483

32. Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP, et al. Serum uric acid levels and multiple health outcomes: Umbrella review of evidence from observational studies, randomized controlled trials, and mendelian randomisation studies. BMJ (2017) 357:j2376. doi:10.1136/bmj.j2376

33. Ponvilawan B, Charoenngam N, Ungprasert P. Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis. Int J Rheum Dis (2020) 23(2):174–80. doi: 10.1111/1756-185x.13740

34. Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American college of physicians clinical guideline. Ann Intern Med (2013) 158(7):535–43. doi: 10.7326/0003-4819-158-7-201304020-00005

35. Abu-Ghanem Y, Shvero A, Kleinnmann N, Winkler HZ, Zilberman DE. 24-h urine metabolic profile: Is it necessary in all kidney stone formers? Int Urol Nephrol (2018) 50(7):1243–7. doi: 10.1007/s11255-018-1902-1

36. Hsi RS, Sanford T, Goldfarb DS, Stoller ML. The role of the 24-hour urine collection in the prevention of kidney stone recurrence. J Urol (2017) 197(4):1084–9. doi: 10.1016/j.juro.2016.10.052

37. Charles PY, Letavernier E, Périé S, Gauthè M, Daudon M, Haymann JP. Effect of parathyroidectomy on renal stone recurrence. Urolithiasis (2021) 49(4):327–34. doi: 10.1007/s00240-020-01239-a